The Weizmann Institute of Science. Discovering Basic Science

Transcription

1 The Weizmann Institute of Science Discovering Basic Science 1

2 THE WEIZMANN INSTITUTE OF SCIENCE FOCUSED ON RESEARCH Professors Heading research groups Administrative staff Scientists Ph.D. s, engineers & technicians Students M.Sc. and Ph.D. only 2

3 THE WEIZMANN INSTITUTE OF SCIENCE FIVE FACULTIES Mathematics Computer Science Chemistry Biology The focus of scientists is excellence in Basic Science Physics Biochemistry 3

4 THE WEIZMANN INSTITUTE OF SCIENCE LEIDEN RANKING 4

5 YEDA INDUSTRY IMPACT 80 companies Established around Yeda s technologies 200 products With Weizmann-Inside technology on the market 2070 patent families Filed since 1971 $22 billion Annual WIS product sales Yeda is the commercialization company with the highest income per researcher worldwide Over 160 patent disclosures were submitted by WIS scientists between

6 LICENSING INCOME SURVEY 2012 TOP 10 UNIVERSITIES * 1 Institution City of Hope National Medical Center. & Beckman Research Licensing Income ($M) NYU Columbia Univ Sloan Kettering Inst. For Cancer Res Massachusetts Institute of Technology (MIT) Princeton University Northwestern University Univ. California System The General Hospital dba Massachusetts General Hos. 10 University of Washington 77 * Source: AUTM Licensing Survey

7 SUCCESS STORIES MULTIPLE SCLEROSIS TREATMENT Other COPAXONE $4,027M Weizmann AVONEX $2,912M Rebif $2,434M COPAXONE and Rebif are two blockbuster treatments for multiple sclerosis developed at the Weizmann institute 7

8 FROM A SINGLE PATENT TO THREE DRUGS EGFR blockers $1,081 MILLION Erbitux Merck and Eli Lilly metastatic colorectal cancer $359 MILLION Vectibix AMGEN Colorectal cancer $500 M (EST 2016) Portrazza Eli Lilly Lung cancer Prof. Sela and colleagues discovered that EGFRinhibiting antibodies produce a synergistic anticancer effect when used together with chemotherapy The three EGFR blockers are saving the lives of hundreds of thousands of cancer patients all over the world 8

9 SUCCESS STORIES HUMIRA AbbVie s leading product, responsible for up to 57% of its overall sales Worldwide sales: $12.54 billion in 2014 HUMIRA was the first fully human monoclonal antibody drug approved by the FDA It was ranked the best selling drug worldwide in

10 TOOKAD Targeted photodynamic therapy A result of collaboration between the Weizmann Institute and Steba biotech Recently approved therapy for prostate cancer in Mexico and in Israel European Phase III clinical trial is currently under evaluation by the EMA TOOKAD Soluble VTP is a day-case procedure lasting approximately 90 minutes. This new minimally invasive technology offers a good alternative to patients diagnosed with early-stage prostate cancer Prof. Avigdor Scherz and Prof. Yoram Salomon 10

11 WORLD LEADING SCIENTISTS PROF. ADA YONATH The pioneer of ribosome crystallography Nobel Laureate in Chemistry, 2009 The first Israeli woman to win the Nobel Prize out of ten Israeli Nobel laureates PROF. ZELIG ESHHAR Developed the first CAR T-cells (novel strategy for cancer treatment with promising results and multibillion dollar market ) 11

12 TURING AWARD LAUREATES PROF. ADI SHAMIR A world leading cryptographer co-inventor of the RSA algorithm for secure data transmission PROF. AMIR PNUELI Received the Turing Award in 1996 for seminal work introducing temporal logic into computing science and for outstanding contributions to program PROF. SHAFI GOLDWASSER Her work on laid the rigorous foundations for modern cryptography and pioneered several themes which are today considered basic to the field 12

13 INTERDISCIPLINARY INNOVATION Dr. Eran Elinav Prof. Eran Segal Host-microbiome interactions and their effects on health and disease Personalized nutrition based on gut microbiome Computer Science and Applied Mathematics A new start-up based on Weizmann science 13

14 THE CURRENT TECHNOLOGY PIPELINE Yeda has a diverse portfolio which covers a broad spectrum of the pharmaceutical and biotech industry Medical Device Diagnostics Research tools Drug Targets Small molecules Antibodies 14

15 PARTNER WITH US TO MAKE THE NEXT SCIENTIFIC BREAKTHROUGH 15